celecoxib has been researched along with transforming growth factor alpha in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bordignon, J; Cecchini, R; da Silva, RV; de Freitas, RC; Goldenberg, S; Lovo-Martins, MI; Malvezi, AD; Martins-Pinge, MC; Neto, EC; Panis, C; Pinge-Filho, P; Tatakihara, VL; Yamada-Ogatta, SF; Zanluqui, NG | 1 |
| Abdel-Fattah, MM; Abo-El Fetoh, ME; Afify, H; Mohamed, WR; Ramadan, LAA | 1 |
2 other study(ies) available for celecoxib and transforming growth factor alpha
| Article | Year |
|---|---|
Inhibition of cyclooxygenase-1 and cyclooxygenase-2 impairs Trypanosoma cruzi entry into cardiac cells and promotes differential modulation of the inflammatory response.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cell Line; Cell Survival; Cells, Cultured; Cyclooxygenase 1; Cyclooxygenase 2; Enzyme-Linked Immunosorbent Assay; Immunity, Innate; Immunohistochemistry; Interleukin-1beta; Myoblasts, Cardiac; Nitric Oxide; Pyrazoles; Rats; Sulfonamides; Transforming Growth Factor alpha; Transforming Growth Factor beta; Trypanosoma cruzi | 2014 |
Cyclooxygenase-2 activates EGFR-ERK1/2 pathway via PGE2-mediated ADAM-17 signaling in testosterone-induced benign prostatic hyperplasia.
Topics: ADAM17 Protein; Animals; Celecoxib; Cyclooxygenase 2; Dinoprostone; ErbB Receptors; Hyperplasia; Inflammation; Male; MAP Kinase Signaling System; Prostatic Hyperplasia; Rats; Rats, Sprague-Dawley; Rats, Wistar; Testosterone; Transforming Growth Factor alpha | 2023 |